Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence study

Weichenthal, M; Ellebaek, E; Mangana, J; Asher, N; Gavrilova, I; Kandolf, L; Ugurel, S; Hausschild, A; Meier, F; Leiter, U; Livingstone, E; Gebhardt, C; Gutzmer, R; Ruhlmann, CH; Mahncke-Guldbrandt, L; Haslund, CA; Kopec, S; Teterycz, P; Bender, M; Poudroux, W; Muñoz-Couselo, E; Berciano-Guerrero, MA; Shalamanova, G; Depalo, DK; Brozic, JM; Chiarion-Sileni, V; Arance, A; Ziogas, D; Robert, C; Velde, AOV; Gassama, AA; Shapira, R; Benbetzalel, G; Grynberg, S; Ramelyte, E; Bertoldo, F; Delprete, V; Gaudy-Marqueste, C; Mohr, P; Dummer, R; Ascierto, PA; Gogas, H; Espinosa, E; Lebbé, C; Rutkowski, P; Haanen, J; Schadendorf, D; Svane, IM – 2025 – 10.1016/j.ejca.2025.115339